Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of parkinson's disease

Molecular Therapy

Volumn 19, Issue 1, 2011, Pages 46-52

  Harms, Ashley S ^a   Barnum, Christopher J ^b   Ruhn, Kelly A ^a   Varghese, Steve ^a   Trevĩo, Isaac ^a   Blesch, Armin ^c,d   Tansey, Mal G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

LENTIVIRUS; PRIMATES; RATTUS;

EID: 78650880194     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.217     Document Type: Article

References (43)

1. Frank-Cannon, TC, Alto, LT, McAlpine, FE and Tansey, MG (2009). Does neuroinfammation fan the fame in neurodegenerative diseases? Mol Neurodegener 4: 47.
2. McGeer, PL and McGeer, EG (2008). Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
3. Aggarwal BB, Samanta, A, Feldmann, M (2000). TNFα. In: Oppenheim JJ, Feldman M (eds) Cytokine Reference. Academic: New York. pp 414-434.
4. Boka, G, Anglade, P, Wallach, D, Javoy-Agid, F, Agid, Y and Hirsch, EC (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172: 151-154.
5. Mogi, M, Harada, M, Riederer, P, Narabayashi, H, Fujita, K and Nagatsu, T (1994). Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fuid from parkinsonian patients. Neurosci Lett 165: 208-210.
6. Nishimura, M, Mizuta, I, Mizuta, E, Yamasaki, S, Ohta, M, Kaji, R et al. (2001). Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 311: 1-4.
7. Ferger, B, Leng, A, Mura, A, Hengerer, B and Feldon, J (2004). Genetic ablation of tumor necrosis factor-α (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89: 822-833.
8. Sriram, K, Matheson, JM, Benkovic, SA, Miller, DB, Luster, MI and O'Callaghan, JP (2002). Mice defcient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16: 1474-1476.
9. Sriram, K, Matheson, JM, Benkovic, SA, Miller, DB, Luster, MI and O'Callaghan, JP (2006). Defciency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α. FASEB J 20: 670-682.
10. McCoy, MK, Martinez, TN, Ruhn, KA, Szymkowski, DE, Smith, CG, Botterman, BR et al. (2006). Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26: 9365-9375.
11. McCoy, MK, Ruhn, KA, Martinez, TN, McAlpine, FE, Blesch, A and Tansey, MG (2008). Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral defcits in hemiparkinsonian rats. Mol Ther 16: 1572-1579.
12. Sauer, H and Oertel, WH (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415.
13. Kaplitt MG, During MJ. Gene Therapy of the Central Nervous System: From Bench to Bedside. Academic Press: Amsterdam; Boston, 2006.
14. Sánchez-Pernaute, R, Ferree, A, Cooper, O, Yu, M, Brownell, AL and Isacson, O (2004). Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinfammation 1: 6.
15. Schallert, T and Jones, TA (1993). "Exuberant" neuronal growth after brain damage in adult rats: the essential role of behavioral experience. J Neural Transplant Plast 4: 193-198.
16. McAlpine, FE, Lee, JK, Harms, AS, Ruhn, KA, Blurton-Jones, M, Hong, J et al. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 34: 163-177.
17. Weiner, WJ (2006). Motor fuctuations in Parkinson's disease. Rev Neurol Dis 3: 101-108.
18. Taylor, L, Jones, L, Tuszynski, MH and Blesch, A (2006). Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J Neurosci 26: 9713-9721.
19. Bialecka, M, Klodowska-Duda, G, Kurzawski, M, Slawek, J, Gorzkowska, A, Opala, G et al. (2008). Interleukin-10 (IL10) and tumor necrosis factor a (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Relat Disord 14: 636-640.
20. Wahner, AD, Sinsheimer, JS, Bronstein, JM and Ritz, B (2007). Infammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol 64: 836-840.
21. McCoy, MK and Tansey, MG (2008). TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinfammation 5: 45.
22. Koprich, JB, Reske-Nielsen, C, Mithal, P and Isacson, O (2008). Neuroinfammation mediated by IL-1 p increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinfammation 5: 8.
23. Kirik, D, Rosenblad, C and Björklund, A (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
24. Lee, CS, Sauer, H and Bjorklund, A (1996). Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72: 641-653.
25. Olanow, CW, Stern, MB and Sethi, K (2009). The scientifc and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl 4): S1-136.
26. Robinson, WH, Genovese, MC and Moreland, LW (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44: 1977-1983.
27. Tweedie, D, Sambamurti, K and Greig, NH (2007). TNF-cc inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 4: 378-385.
28. Van Oosten, BW, Barkhof, F, Truyen, L, Boringa, JB, Bertelsmann, FW, Von Blomberg, BM et al. (1996). Increased MRI activity and immune activation in two multiple sclerosis patients treated with the onoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
29. Olleros, ML, Guler, R, Vesin, D, Parapanov, R, Marchal, G, Martinez-Soria, E et al. (2005). Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 166: 1109-1120.
30. Steed, PM, Tansey, MG, Zalevsky, J, Zhukovsky, EA, Desjarlais, JR, Szymkowski, DE et al. (2003). Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898.
31. Arnett, HA, Mason, J, Marino, M, Suzuki, K, Matsushima, GK and Ting, JP (2001). TNF a promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4: 1116-1122.
32. Kassiotis, G, Bauer, J, Akassoglou, K, Lassmann, H, Kollias, G and Probert, L (1999). A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodefcient mice. Eur J Immunol 29: 912-917.
33. Fontaine, V, Mohand-Said, S, Hanoteau, N, Fuchs, C, Pfzenmaier, K and Eisel, U (2002). Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216.
34. 2+ accumulation. Proc Natl Acad Sci USA 92: 9328-9332.
35. Janelsins, MC, Mastrangelo, MA, Park, KM, Sudol, KL, Narrow, WC, Oddo, S et al. (2008). Chronic neuron-specifc tumor necrosis factor-cc expression enhances the local infammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 173: 1768-1782.
36. Kaplitt, MG (2010). Parkinson disease: another player in gene therapy for Parkinson disease. Nat Rev Neurol 6: 7-8.
37. Lim, ST, Airavaara, M and Harvey, BK (2010). Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61: 14-26.
38. Jarraya, B, Boulet, S, Ralph, GS, Jan, C, Bonvento, G, Azzouz, M et al. (2009). Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1: 2-4.
39. Pfeifer, A, Ikawa, M, Dayn, Y and Verma, IM (2002). Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 99: 2140-2145.
40. Woodlee, MT, Asseo-García, AM, Zhao, X, Liu, SJ, Jones, TA and Schallert, T (2005). Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol 191: 310-317.
41. Frank-Cannon, TC, Tran, T, Ruhn, KA, Martinez, TN, Hong, J, Marvin, M et al. (2008). Parkin defciency increases vulnerability to infammation-related nigral degeneration. J Neurosci 28: 10825-10834.
42. West, MJ, Slomianka, L and Gundersen, HJ (1991). Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
43. German, DC and Manaye, KF (1993). Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J Comp Neurol 331: 297-309.